We focus our analysis on NPM1, an established measurable residual disease (MRD) by recent ELN recommendation,21 and on IDH2, an often mutated gene we have previously shown to be used in MRD follow-up of AML patients.20 This evidence concerns the gene IDH2 and acute myeloid leukemia.